Quarterly Report Q1 2026: Orviglance(R) Approaching Transformative Milestones
Ascelia Pharma AB (publ) (STO:ACE) today published its Interim Report Q1 for 2026 (January - March), which is now available on the company's website: Financial Reports - ASCELIAKEY EVENTS IN Q1 2026Abstract with Orviglance data has been accepted for oral presentation at the annual radiology congress ESGAR 2026Management changes: Anton Hansson starts as CFO, while Julie Waras Brogren leaves her position as Deputy CEOKEY EVENTS AFTER THE...
Read more








